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3.1
GENETIC ANALYSIS OF THE TYLOSIS WITH OESOPHAGEAL 
CANCER (TOC) GENE REGION ON 17Q25
F.E. McRonald 1, L. Rowbottom 1, J.E. Langan 1, A. Ellis 2,
J.M. Shaw 2, J.K. Field 1, J.M. Risk 1
1 The University of Liverpool, Liverpool, United Kingdom,
2 Royal Liverpool and Broadgreen University Hospital, Liverpool,
United Kingdom
Tylosis (focal non-epidermolytic palmoplantar keratoderma) is associated 
with the early onset of squamous cell oesophageal cancer in two large 
families from the UK and US and a smaller German pedigree. The familial 
cancer association is rare, but the gene is also implicated in the development 
of sporadic squamous cell oesophageal cancer. Our recent haplotype and 
linkage analyses using 9 novel microsatellite markers and 52 novel single 
nucleotide polymorphisms have reduced the minimal region on chromosome 
17q25 from ~500kb to ~38kb.  This region contains one complete gene and 
partial coding sequences of two other genes. Mutational analysis of the 
coding regions of the candidate genes did not identify any disease-associated 
mutations.  Sequencing of the 38kb region in UK and US family members 
has identiﬁ  ed 2 genetic alterations for further investigation as potentially 
disease-causing, although neither of these is located within known gene 
coding regions. The gene that is contained entirely within the minimal 
region has recently been identiﬁ  ed as cytoglobin (CYGB), or Stellate-cell 
Activation-associated Protein (STAP).  Using RT-PCR, we have shown that 
CYGB is ubiquitously expressed, suggesting that its function is not merely a 
hepatic one. However, expression of CYGB is down-regulated in oesophageal 
biopsies from tylosis patients in comparison with normal oesophagus and is 
alternatively spliced. Although no disease-speciﬁ  c sequence changes are 
evident in the coding region of STAP, the regulatory and intronic regions are 
candidate sites for causative mutations.  
The identiﬁ  cation and characterisation of the TOC gene could, therefore, 
contribute to the understanding of this commonly occurring cancer.  A 
molecular marker such as this could potentially have applications in cancer 
screening or rational drug design.
3.2
ROLE OF GASTRIN IN H. PYLORI INDUCED HB-EGF GENE
UP-REGULATION AND ECTODOMAIN SHEDDING
J Dickson 1, A Grabowska 1, J Atherton 2, SA Watson 1
1 Academic Unit of Cancer Studies, University of Nottingham, 
Nottingham, United Kingdom, 2 Division of Gastroenterology, 
University of Nottingham, Nottingham, United Kingdom
Heparin-binding epidermal growth factor-like growth factor (HB-EGF)
is expressed in a propeptide form that is tethered to the cell membrane.
The mature growth factor is cleaved to exert an effect on cells via binding
to the EGF-receptor. This process can be induced by a number of factors
including exposure to H. pylori. The aim of this work was to investigate
the role of gastrin in H. pylori induced HB-EGF gene up-regulation and
ectodomain shedding in gastric cells. 
Wild-type gastric adenocarcinoma cell lines, AGS cells transfected to
express human CCK2 receptors (classical and Intron 4 isoforms) and gastric
cells transfected with a gastrin anti-sense plasmid were co-cultured with
either gastrin and/or the cag+ vacA s1/m1 toxigenic strain 60190 or the
cag– vacA s2/m2 nontoxigenic strain Tx30a of H. pylori. Western blotting
and ELISA were used to determine levels of HB-EGF ectodomain shedding,
whilst gastrin and HB-EGF gene expression were measured using real-time
PCR.  Statistical analysis was performed using one-way ANOVA. 
H. pylori signiﬁ  cantly up-regulated expression of HB-EGF and gastrin genes
in wild-type gastric cells (p<0.003). Addition of exogenous gastrin with H.
pylori further increased HB-EGF gene expression in cell lines that did not
respond to gastrin alone (p<0.002). Analysis by Western blot and ELISA
conﬁ  rmed that this trend was repeated at the protein level (p<0.001). 
AGS CCK2 receptor transfected cells exhibited greater up-regulation of
HB-EGF and gastrin gene expression than both the Intron 4 isoform and
vector control transfected cell lines (p<0.004). Gastrin anti-sense cells
displayed a lower degree of HB-EGF gene up-regulation and ectodomain
shedding than vector control (p<0.001). 
H. pylori can up-regulate gastrin and HB-EGF gene expression, and
HB-EGF ectodomain shedding. This effect appears to be mediated by
exogenous and cell-associated gastrin possibly via the CCK-2 receptor.
3.3
THE EFFECT OF TRANSCATHETER ARTERIAL 
CHEMOEMBOLIZATION ON ANGIOGENESIS AND THE 
EXPRESSION OF VEGF IN HEPATOCELLULAR CARCINOMA
B Wang 1, ZQ Gao 2, H Xu 1, GW Cao 1, YQ Sun 1, DX Yu 1, HF Ning 1
1 Department of Radiology, the Afﬁ  liated Hospital, Weifang Medical 
University, Weifang, China, 2 Department of Medical Biology, Weifang 
Medical University, Weifang, China
Introduction Hepatocellular carcinoma (HCC) is one of the most common 
cancers in China and the Asian. The effection of the treatment in HCC both 
TACE and the surgical resection has some limitation. The objective of this 
study is to investigate intratumor microvessel density (MVD), expression 
of vascular endothelial growth factor (VEGF) in survival cancerous tissue 
in HCC after TACE. 
Methods The specimens of HCC in 63 cases veriﬁ  ed by histopathology 
were studied, which included 42 cases treated with surgical resection alone 
(the control group), and 21 cases undergoing 1-2 times TACE therapy 
prior to the surgical resection (the TACE group). The medicine and the 
emblization materials including 5-Fu, DDP, PHT-ADM, HCPT, lipiodol 
and absorbable gelatin sponge were infused through hepatic artery once 
time in the TACE group. The MVD, diameter of microvessel and VEGF 
protein expression in HCC tissue were measured respectively. 
Results The MVD was 51.69 ± 18.17 in the control group and 58.57 ± 
15.75 in the TACE group. There was no signiﬁ  cant difference between the 
two groups (t = 1.48, P > 0.05). The diameter of microvessel was 17.62 
± 10.54 µm in the control group and 15.79 ± 7.65µm in the TACE group. 
There was no signiﬁ  cant difference between the two groups (t = 0.71, P 
> 0.05). The cell number of VEGF expression was 243.66 ± 88.88 in the 
TACE group, that was higher than in the control group (138.26 ± 65.24) (t 
= 5.34, P < 0.01). There was a positive correlation between the expression 
of VEGF and MVD (r = 0.4936, t = 4.4329, P < 0.05).
Conclusion The study indicates that the survival cancerous tissue in HCC 
after TACE has rich vascularity and expression of VEGF of the survival 
cancerous cells can be enhanced by TACE which may play an important 
role in re-establishment of blood supply to HCC after TACE.
3.4
MICROARRAYS IDENTIFY PROGNOSTIC PROFILES IN COLON 
CANCER PATIENTS AND POTENTIAL MECHANISMS OF 5FU 
CHEMORESISTANCE
ESR Collie-Duguid 1, GI Murray 1, DS Stewart 1, D Bissett 2,
J Cassidy 3, LM Samuel 2
1 University of Aberdeen, Aberdeen, United Kingdom, 2 Aberdeen 
Royal Inﬁ  rmary, Aberdeen, United Kingdom, 3 University of Glasgow, 
Glasgow, United Kingdom
Chemoresistance to current 5-ﬂ   uorouracil (5FU) based therapies is a
signiﬁ  cant clinical problem in colorectal cancer treatment, with only around
40% of patients alive 5 years after diagnosis. Informative and accurate pre-
therapy data is required to guide clinical decisions and allow individualisation
of patient treatment.  
Expression levels of over 22000 transcripts were measured in surgical
resection specimens of moderately differentiated tumour (T) and uninvolved
adjacent (N) tissues from Dukes’ C colon cancer patients, using Affymetrix
HG-U133A GeneChips™.  All patients received adjuvant 5-ﬂ  uorouracil
therapy following potentially curative resection of their primary tumour
and were classiﬁ  ed according to disease-free survival (long >45m or short
<8m).  Data was analysed using Affymetrix MASv5, MicroDBv3, DMTv3
and GeneSpringv6.1.  
The expression patterns of a threshold and probability ﬁ   ltered subset of
17 genes differentiated tumour and uninvolved tissues in all patients in
unsupervised hierarchical clustering and predicted histological diagnosis class
with 100% accuracy and high predictive strength (p ratio <0.032), in leave
one out cross-validation. A subset of genes, differentially expressed between
long and short survivors in tumour tissues ( 2fold, p<0.01), differentiated
patients with different survival phenotypes, using unsupervised hierarchical
clustering. An accurate (100%) and strong (p ratio <0.12) prediction rule for
patient survival was built from the expression patterns of these genes.  
Supervised analysis of ontological groups important in tumorigenesis and/
or 5FU chemoresistance, demonstrated that key factors, including cell cycle,
apoptotic and pyrimidine metabolic genes, were associated with tumorigenesis
or patient survival in colon cancer patients.  Global examination of abnormal
gene expression proﬁ  les in colon tumours, has identiﬁ  ed potential molecular
determinates of prognosis and suggested possible mechanisms of 5FU
chemoresistance.
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QUASAR: A RANDOMISED STUDY OF ADJUVANT 
CHEMOTHERAPY (CT) VS OBSERVATION INCLUDING 3239 
COLORECTAL CANCER PATIENTS
The QUASAR Collaborative Group 
United Kingdom, QUASAR Study Ofﬁ  ce, University of Birmingham, 
Birmingham
Background: It is unclear whether adjuvant ﬂ  uorouracil/
folinic acid (FUFA) CT produces worthwhile survival 
beneﬁ   ts for patients with node negative colorectal cancer.
Methods: Patients with apparently curative resections of colon 
or rectal cancer were randomised following surgery between 
FUFA and observation (with CT considered on recurrence). CT 
consisted of either six 5-day, four-weekly or 30 once-weekly 
courses of intravenous ﬂ  uorouracil  (370mg/m2) with either high-
dose (175mg) or low-dose (25mg) L-folinic acid, and with either 
levamisole or placebo. Primary outcome was all cause mortality.
Results: Between June 1994 and December 2003, 3239 patients 
(91% Dukes B, 71% colon cancer, median age 63) from 150 centres 
in 17 countries were randomised between CT and observation and 
4927 between CT regimens. No beneﬁ  t was seen for high-dose FA or 
levamisole (2000, Lancet; 355:1588). With a median follow-up of 4.2 
years, risk of death with CT vs control was 0.85 (95%CI 0.72-1.00; 
p=0.05) and recurrence 0.81 (0.69-0.95; p=0.01). Treatment efﬁ  cacy 
did not differ signiﬁ  cantly by stage, site, age or schedule. Differences 
between CT and observation were seen only for QoL measurements 
directly related to toxicity (diarrhoea, nausea, vomiting, fatigue, 
appetite loss and mouth pain; all p<0.001), and only during CT.
Conclusions: These inexpensive and relatively low toxicity 
chemotherapy regimens produce a small (1% - 5%) survival beneﬁ  t for 
stage B patients, which is sufﬁ  cient to outweigh the inconvenience and 
cost for high-risk and younger patients. Longer follow-up and meta-
analysis of all trials is needed to clarify the balance of beneﬁ  ts and 
disbeneﬁ  ts for older patients.
3.6
CAN MOLECULAR MARKERS PREDICT BOTH RESPONSE TO 
TREATMENT AND CLINICAL OUTCOME IN SQUAMOUS CELL 
CARCINOMA OF THE ANUS 
S Mawdsley 1, R Glynne-Jones 1, S Bentzen 1, F Daley 1, G Wilson 1,
A Makris 1, H Meadows 3, R James 2
1 The Gray Cancer Institute, Middlesex, United Kingdom, 2 Anal 
Cancer Trials Management Group, London, United Kingdom, 3 CRUK,
MRC & UCL trials centres, London, United Kingdom
Aim: The prognostic and predictive value of a panel of molecular markers and
clinicopathological variables in anal cancer were explored.      
Methods: Tumour samples from 230 patients entered into the UKCCCR ACT I trial
were studied. 124 received radiation alone (RT) and 106 concurrent mitomycin/5FU/
RT (CMT). T stages: T1:33, T2:80, T3:88, T4:29. Median age 63 yrs, male: female
ratio 43:57%, median follow-up 46 months. An immunohistochemical analysis of
p53, bcl-2, Ki67, thymidylate synthase, thymidine phosphorylase (TP), cyclins
D1/A, DPD, CA9 and CD34 was undertaken. The primary endpoint was disease-
free survival (DFS), with secondary endpoints of cause-speciﬁ  c survival (CSS) and
treatment response.  
Results: Several markers on multivariate analyses were independent predictors
of each survival endpoint, see table. CD34 (p=0.014), T stage (p<0.001) and TP
expression (p<0.001) predicted an improved DFS in the CMT arm. Stage (p<0.001)
and p53 expression (p=0.030) predicted a poorer response to treatment and in the
RT alone arm decreasing cyclin A (p=0.018) and increasing bcl-2 (p=0.030) also
predicted for a poorer response. Response predicted survival (p<0.000).
Conclusion: This is one of the largest studies examining the role of molecular
markers in anal cancer, demonstrating that outcome and treatment response can
be predicted independently of standard clinicopathological characteristics. Making
tailoring the treatment to the individual a future possibility.
DFS P HR CSS P HR
T 0.000 1.77 T 0.000 2.04
N 0.008 1.70 N 0.008 1.74
CD34 0.038 0.99 P53 0.021 1.28
TP 0.000 1.46 Tarm 0.000 2.34
Tarm 0.000 2.8
3.7
DOES HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) 
AFFECT THE INCIDENCE OR OUTCOME OF INVASIVE ANAL 
CANCER?
A Waterston , C Thirlwell , T Newsom-Davis , T Powles , M Nelson ,
B Gazzard , M Bower 
Chelsea & Westminster Hospital, London, United Kingdom
Background: The incidence of invasive anal carcinoma is increased 
amongst people with HIV . The effects of HAART on anal cancer incidence 
and outcome are unknown. 
Methods: The anal cancer incidence in our prospective cohort of 8,640 HIV 
positive individuals (40,126 patient years of follow-up) was measured in 
pre (1984-95) and post (1996-2003) HAART eras and compared to the age 
and gender matched general population of SE England for 1995 (3.1 x106) 
collected by the Thames Cancer Registry. 
Results: The incidence of anal cancer in our HIV+ cohort is 60/105 patient 
years (PY). This is 120 times higher than in the matched population. The 
incidence was 35 (95% CI: 15-72) /105 PY in the pre HAART era and 92 
(95% CI: 52-149) /105 PY in the post HAART era: giving relative risks 
of 67 and 176 respectively (p<0.001 for both). 26 HIV+ patients with 
histologically conﬁ  rmed invasive anal cancer were identiﬁ  ed. The median 
age at presentation of anal cancer is 43 years (range 28-56) and CD4 cell 
count is 206 cells/mm3 (16-749). 12 were receiving HAART but only 5 
(42%) had undetectable HIV-1 viral loads. 22 patients were treated with 
chemoradiotherapy, 2 tumours conﬁ  ned to the anal verge were completely 
excised and 2 patients received palliative care only. Median follow-up is 
4.8 years, 11 patients have died (7 from anal cancer and 4 in remission). 
The overall survival at 5 years is 47% (95% CI: 24-70%). There is no 
difference in overall survival between the pre and post HAART eras (Log 
rank p=0.19).
Conclusions: HAART has not reduced the incidence of anal cancer. This 
cohort study is the largest series reported thus far. The 5 year overall survival 
is worse than for the general population, however, the 2 year survival rate 
is 74% with no relapses of anal cancer occurring after this time and all 
subsequent deaths attributed to HIV infection. These results are encouraging 
as they include 2 patients who received palliative care only.
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